Gut: The effect of Lansolazole and famotiden in preventing relapsed idyllytic gastric duodenal ulcer bleeding direction

Patients with a history of Helicobacter pyrethroid-negative idly ill haemorrhagic ulcers had a higher risk of complications of relapsed ulcers.
study assumed that proton pump inhibitors (Lansolazi) were superior to histamine 2-subject antagonists (famotide) and could prevent relapsed ulcer bleeding in such patients, the results of which were published online in Gut.
the double-blind, randomized trial, the researchers recruited patients with a history of idexual hemorrhagic ulcers.
the ulcer healed, the patient was randomly assigned (1:1) daily oral lanso laazole 30 mg or famotin 40 mg for 24 months.
end of the disease is relapsed upper digestive tract bleeding within 24 months, which is analyzed in the intended treatment population.
2010-2018, researchers recruited 228 patients (114 patients in each group).
patients who received lansolazole (duodenal ulcers) and 3 patients who received famotin (2 stomach ulcers and 1 duodenal ulcer) had relapsed upper gastrointestinal bleeding.
0.88% (95% CI 0.08% to 4.37%) and 2.63% (95%) of relapsed upper gastrointestinal bleeding in the 24-month relapsed upper digestive tract bleeding in the Lansolazo and Famotin groups % CI 0.71% to 6.91%) (P-0.313; HR 0.33,95% CI 0.03-3.16, P-0.336).
patients were not using aspirin, nonsteroidal anti-inflammatory drugs or other anti-thrombosis drugs.
, the two-year double-blind randomized trial showed that in patients with a history of Helicobacter pylhoid-negative idyllytic ulcer bleeding, the relapsed blood rate of lanso laazole and famotin users was comparable, but the small difference in efficacy could not be ruled out.
。